Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Growth

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2026Mar2025Mar2024Mar2023Mar2022
   Core EBITDA Growth(%) 31.25-1.3818.82-27.0420.67

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is 31.25 based on Mar2026 Consolidated results.
Year Core EBITDA Growth
Mar202631.25
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2026 31.25
Positive
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹47,414.4 Cr -1.4% 0.2% 47.3% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹434,280.0 Cr -2.4% -6.2% 11.8% Stock Analytics
DIVIS LABORATORIES ₹246,737.0 Cr -3.3% 1.4% 57.4% Stock Analytics
TORRENT PHARMACEUTICALS ₹181,129.0 Cr -4.5% -4% 35.9% Stock Analytics
CIPLA ₹108,808.0 Cr -3.6% -5% -10.6% Stock Analytics
DR REDDYS LABORATORIES ₹100,170.0 Cr -0.2% 2.5% -3% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-1.4%

0.2%

47.3%

SENSEX

-2.3%

-6.6%

-12%


You may also like the below Video Courses